secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001213900-22-068819
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Q3 net loss $7.7M; cash $107.1M; TARA-002 trials progressing
--------------------------------------------------------------------

- Net loss of $7.7M ($0.68/share) vs. $10.8M ($0.96) in Q3 2021; includes $1.4M stock-based compensation.
- Cash and investments $107.1M as of Sep 30, 2022; expected to fund operations into 2H2024.
- R&D expense $3.5M, down from $4.1M; G&A $4.5M, down from $6.7M year-over-year.
- Phase 1a dose escalation of TARA-002 in NMIBC ongoing; Phase 2 in LMs expected to start in 2023 after FDA feedback.
- IV Choline Chloride IFALD study ongoing; results to inform next steps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022068819/0001213900-22-068819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022068819/ea167960-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-068819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer